<html lang="en" class="pb-page js" data-request-id="94d6759910a6f1f3-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6759910a6f1f3-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/JG1F8BuMrBJQxusONfQ4veKiunfS7rgd30j2qmDhxDw9wGqiNNSx4w9ZvnBZ90cSBKKkVOw180TeKfm-t6TQyw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Sotatercept for the Treatment of Pulmonary Arterial Hypertension | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6759910a6f1f3-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.2072370209280332"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Pulmonary/Critical Care General">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Pulmonary/Critical Care"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2024277","title":"Sotatercept for the Treatment of Pulmonary Arterial Hypertension","category":"Research","type":"Original Article","topics":"Pulmonary/Critical Care General","specialties":"Pulmonary/Critical Care","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-04-01T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Pulmonary/Critical Care General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Pulmonary/Critical Care\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2024277","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6759910a6f1f3-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Sotatercept for the Treatment of Pulmonary Arterial Hypertension"><meta name="dc.Creator" content="Marc Humbert"><meta name="dc.Creator" content="Vallerie McLaughlin"><meta name="dc.Creator" content="J. Simon R. Gibbs"><meta name="dc.Creator" content="Mardi Gomberg-Maitland"><meta name="dc.Creator" content="Marius M. Hoeper"><meta name="dc.Creator" content="Ioana R. Preston"><meta name="dc.Creator" content="Rogerio Souza"><meta name="dc.Creator" content="Aaron Waxman"><meta name="dc.Creator" content="Pilar Escribano Subias"><meta name="dc.Creator" content="Jeremy Feldman"><meta name="dc.Creator" content="Gisela Meyer"><meta name="dc.Creator" content="David Montani"><meta name="dc.Creator" content="Karen M. Olsson"><meta name="dc.Creator" content="Solaiappan Manimaran"><meta name="dc.Creator" content="Jennifer Barnes"><meta name="dc.Creator" content="Peter G. Linde"><meta name="dc.Creator" content="Janethe de Oliveira Pena"><meta name="dc.Creator" content="David B. Badesch"><meta name="dc.Description" content="Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is..."><meta name="Description" content="Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-04-01"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2024277"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202104013841306"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2036314"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2024277">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2024277">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2024277">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Sotatercept for the Treatment of Pulmonary Arterial Hypertension | NEJM">
        <meta property="og:title" content="Sotatercept for the Treatment of Pulmonary Arterial Hypertension | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2024277">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/1e670798-fc31-46f9-a5ab-9dce089749e3/nejmoa2024277_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/1e670798-fc31-46f9-a5ab-9dce089749e3/nejmoa2024277_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling,
cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic
protein pathway signaling is...">
        <meta name="twitter:description" content="Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling,
cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic
protein pathway signaling is...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2095">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2024277">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2024277">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.384.issue-13;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2024277;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024277" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024277" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024277" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2024277" class="inputDoi"><input type="hidden" value="M. Humbert and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1204-1215" class="inputCitation"><input type="hidden" value="03-31-2021" class="inputEPubDate"><input type="hidden" value="April 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Sotatercept for the Treatment of Pulmonary Arterial Hypertension" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6759910a6f1f3-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Sotatercept for the Treatment of Pulmonary Arterial Hypertension</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Marc</span> <span property="familyName">Humbert</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vallerie</span> <span property="familyName">McLaughlin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">J. Simon R.</span> <span property="familyName">Gibbs</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mardi</span> <span property="familyName">Gomberg-Maitland</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marius M.</span> <span property="familyName">Hoeper</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ioana R.</span> <span property="familyName">Preston</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1378-7362" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1378-7362</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rogerio</span> <span property="familyName">Souza</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2789-9143" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2789-9143</a></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+11</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aaron</span> <span property="familyName">Waxman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pilar</span> <span property="familyName">Escribano Subias</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jeremy</span> <span property="familyName">Feldman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gisela</span> <span property="familyName">Meyer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Montani</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Karen M.</span> <span property="familyName">Olsson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Solaiappan</span> <span property="familyName">Manimaran</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jennifer</span> <span property="familyName">Barnes</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter G.</span> <span property="familyName">Linde</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Janethe</span> <span property="familyName">de Oliveira Pena</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">David B.</span> <span property="familyName">Badesch</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the PULSAR Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-11</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 31, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1204</span>-<span property="pageEnd">1215</span></div><div class="doi">DOI: 10.1056/NEJMoa2024277</div><div class="core-enumeration"><a href="/toc/nejm/384/13"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">13</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMarc%2BHumbert%252C%2BVallerie%2BMcLaughlin%252C%2BJ.%2BSimon%2BR.%2BGibbs%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2024277%26title%3DSotatercept%2Bfor%2Bthe%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%26publicationDate%3D04%252F01%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2024277" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMarc%2BHumbert%252C%2BVallerie%2BMcLaughlin%252C%2BJ.%2BSimon%2BR.%2BGibbs%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2024277%26title%3DSotatercept%2Bfor%2Bthe%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%26publicationDate%3D04%252F01%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ecc3b742-7f4a-408b-85d6-3c9103bc9fc6/nejmoa2024277.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2024277.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024277" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2024277" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024277.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this 24-week multicenter trial, we randomly assigned 106 adults who were receiving background therapy for pulmonary arterial hypertension to receive subcutaneous sotatercept at a dose of 0.3 mg per kilogram of body weight every 3 weeks or 0.7 mg per kilogram every 3 weeks or placebo. The primary end point was the change from baseline to week 24 in pulmonary vascular resistance.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Baseline characteristics were similar among the three groups. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline to week 24 in pulmonary vascular resistance was −145.8 dyn·sec·cm<sup>−5</sup> (95% confidence interval [CI], −241.0 to −50.6; P=0.003). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −239.5 dyn·sec·cm<sup>−5</sup> (95% CI, −329.3 to −149.7; P&lt;0.001). At 24 weeks, the least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline in 6-minute walk distance was 29.4 m (95% CI, 3.8 to 55.0). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was 21.4 m (95% CI, −2.8 to 45.7). Sotatercept was also associated with a decrease in N-terminal pro–B-type natriuretic peptide levels. Thrombocytopenia and an increased hemoglobin level were the most common hematologic adverse events. One patient in the sotatercept 0.7-mg group died from cardiac arrest.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. (Funded by Acceleron Pharma; PULSAR ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03496207" target="_blank">NCT03496207</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Pulmonary arterial hypertension is a rare, progressive disorder characterized by pulmonary vascular remodeling, resulting in high pulmonary artery pressure and progressive right ventricular dysfunction.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3" href-manipulated="true">1-3</a></sup> Current treatments, which target the prostacyclin, endothelin-1, or nitric oxide pathways, slow disease progression. However, the 5-year survival rate of approximately 60% highlights the need for therapies targeting alternative pulmonary vascular remodeling pathways.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r4 r5 r6 r7" id="body-ref-r7" href-manipulated="true">1,4–7</a></sup></div><div role="paragraph">Mutations in bone morphogenetic protein (BMP) receptor type 2 (<i>BMPR2</i>) — a member of the transforming growth factor β (TGF-β) superfamily — are a major factor underlying heritable pulmonary arterial hypertension; the BMPR-II signaling pathway is also important in development of the disease in patients without heritable disease.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10 r11" id="body-ref-r11" href-manipulated="true">8-11</a></sup> Owing to the role of the BMPR-II pathway in maintaining endothelial integrity in pulmonary arteries, mutations that reduce signaling in this pathway promote endothelial dysfunction, increased cellular proliferation, and pulmonary vascular remodeling.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r12 r13 r14 r15 r16" id="body-ref-r16" href-manipulated="true">9,10,12–16</a></sup></div><div role="paragraph">Sotatercept is a novel, first-in-class fusion protein composed of the extracellular domain of the human activin receptor type IIA fused to the Fc domain of human IgG1. Sotatercept acts as a ligand trap for members of the TGF-β superfamily, thus restoring balance between the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway (<a href="#f1">Figure 1</a>).<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-1" href-manipulated="true" aria-label="Reference 17">17</a></sup> Sotatercept has been evaluated in healthy volunteers, in patients with hematologic disorders, and in patients with conditions characterized by a dysfunctional TGF-β superfamily signaling pathway, including bone loss, chemotherapy-induced anemia, multiple myeloma, myelodysplastic syndromes, β-thalassemia, and end-stage kidney disease.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19 r20 r21 r22 r23 r24" id="body-ref-r24-1" href-manipulated="true">18-24</a></sup> In the PULSAR trial, we investigated the safety and efficacy of sotatercept in patients with pulmonary arterial hypertension who were receiving background therapy for pulmonary hypertension.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f1.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/1e670798-fc31-46f9-a5ab-9dce089749e3/assets/images/large/nejmoa2024277_f1.jpg" height="2095" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Proposed Mechanism of Action for Sotatercept in Pulmonary Arterial Hypertension.</div><div class="notes"><div role="doc-footnote">The proposed mechanism of action involves rebalancing growth-promoting and growth-inhibiting signaling. Pulmonary arterial hypertension is associated with dysregulation of the bone morphogenetic protein (BMP) receptor type II (BMPR-II)–Smad1/5/8 pathway in pulmonary vascular smooth muscle and endothelial cells, causing an imbalance between proproliferative and antiproliferative signaling pathways. BMPR-II–Smad1/5/8 pathway down-regulation leads to increased production of activin ligands, such as activin A, growth differentiation factor 8 (GDF8), and GDF11, which contributes to activin receptor type IIA (ActRIIA)–Smad2/3 pathway up-regulation. Increased phosphorylated Smad (pSmad)2/3 activity promotes expression of the endogenous BMP antagonists gremlin-1 and noggin.Gremlin-1 and noggin further reduce BMP–Smad1/5/8 signaling. The overall result is that antiproliferative signaling is reduced, shifting the balance toward proproliferative activin–Smad2/3 signaling, which leads to pulmonary vascular remodeling. Sotatercept acts to sequester excess ActRIIA ligands, thereby reducing ActRIIA–Smad2/3 signaling to rebalance growth-promoting and growth-inhibiting signaling. ALK denotes activin receptor–like kinase.</div></div></figcaption></figure></div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">PULSAR is a multicenter, randomized, double-blind, phase 2 trial that includes a 24-week placebo-controlled treatment period, followed by an 18-month active-drug extension period that is currently ongoing. Here, we report the main results from the 24-week placebo-controlled period.</div><div role="paragraph">A steering committee designed the trial in collaboration with the sponsor, Acceleron Pharma. An institutional review board or independent ethics committee at each trial center approved the <a href="#ap1">protocol</a>. An independent data and safety monitoring committee reviewed unblinded safety data collected 6 weeks after the first dose of sotatercept or placebo was administered. The trial was conducted in accordance with the principles of the Declaration of Helsinki, the international ethical guidelines of the Council for International Organizations of Medical Sciences, the Good Clinical Practice guidelines of the International Council for Harmonisation, and applicable laws and regulations.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26 r27" id="body-ref-r27" href-manipulated="true">25-27</a></sup></div><div role="paragraph">In addition to its role in the design of the trial, the sponsor selected the participating trial centers; oversaw the conduct and monitoring of the trial, which were performed by a contract research organization (PPD); received and maintained the trial database; and performed all the data analyses. No independent analyses of the data were performed. The academic authors had the authority to request additional analyses. All the authors vouch for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the <a href="#ap1">protocol</a> and the statistical analysis plan, which are available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients had confirmed pulmonary arterial hypertension (group 1 of the updated World Health Organization [WHO] classification of pulmonary hypertension) in WHO functional class II or III (classes range from I to IV, with higher numbers indicating greater functional limitations), excluding the subtypes associated with portopulmonary disease, schistosomiasis, and human immunodeficiency virus infection.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> A full list of inclusion and exclusion criteria is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org. Patients were receiving stable background therapy for pulmonary arterial hypertension for at least 90 days before enrollment in the trial and continued to receive the treatment during the course of the trial. The treatment consisted of monotherapy, double therapy, or triple therapy with combinations of endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, or prostacyclin-receptor agonists. All the patients provided written informed consent.</div></section><section id="sec-1-3"><h3>Procedures</h3><div role="paragraph">Initially, eligible patients were stratified according to baseline WHO functional class and were randomly assigned in a 1:1:1 ratio by an interactive response technology system to one of three groups: placebo, sotatercept at a dose of 0.3 mg per kilogram of body weight, or sotatercept at a dose of 0.7 mg per kilogram. During the trial, the randomization ratio was changed to 3:3:4 to increase the statistical power with respect to the sotatercept 0.7-mg group; 7 patients had been enrolled at the time of this change. Sotatercept or placebo (saline) was administered by means of subcutaneous injection every 21 days.</div><div role="paragraph">Safety and efficacy were assessed at screening and every 3 weeks thereafter for 24 weeks. Adverse events were recorded from the time of screening until 8 weeks after the end of the placebo-controlled treatment period. Patients who completed the placebo-controlled treatment period continued directly into the 18-month extension period; the recording of adverse events continues in the extension period. Dose modifications were planned in accordance with guidance from the European Medicines Agency (as outlined in Table S1 in the <a href="#ap2">Supplementary Appendix</a>) for any occurrences of leukopenia, neutropenia, or thrombocytopenia or increases in hemoglobin levels or blood pressure. These adverse events have been reported in previous trials of sotatercept. Patients who discontinued sotatercept or placebo or withdrew consent were asked to return for the end-of-trial visit.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was the change from baseline to week 24 in pulmonary vascular resistance. The key secondary end point was the change from baseline to week 24 in 6-minute walk distance. Other secondary efficacy end points included the change from baseline to week 24 in N-terminal pro–B-type natriuretic peptide (NT-proBNP) level, systolic excursion of the tricuspid annular plane (assessed by echocardiography), WHO functional class, clinical worsening, scores on the Cambridge Pulmonary Hypertension Outcome Review, and scores on the 36-Item Short-Form Health Survey (SF-36). Safety end points included adverse events and clinical laboratory test results. A complete list of the trial end points is provided in Table S2.</div><div role="paragraph">Pulmonary vascular resistance was calculated with the use of the mean pulmonary artery pressure, the pulmonary artery wedge pressure, and the cardiac output, all of which were measured by catheterization of the right side of the heart at screening and at week 24 of the placebo-controlled treatment period. Echocardiograms (two-dimensional) were obtained according to a prespecified protocol and were approved, reviewed, and analyzed in a blinded manner at a central laboratory (BioTel Research). End points were assessed at baseline and at selected trial visits. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. The methods used for catheterization and echocardiography, as well as descriptions of the end point of clinical worsening and the grades used in the CTCAE, are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The sample-size calculation for the trial was based on the following assumptions: a baseline mean (±SD) pulmonary vascular resistance of 800±400 dyn·sec·cm<sup>−5</sup>; a 30% reduction in mean pulmonary vascular resistance (240 dyn·sec·cm<sup>−5</sup>) at 24 weeks in the sotatercept groups and no change in the placebo group; a one-sided alpha level of 0.10 and 80% power to detect the difference among groups; and dropout rates of 15% in the placebo group, 15% in the sotatercept 0.3-mg group, and 35% in the sotatercept 0.7-mg group. The estimated dropout rate in the sotatercept 0.7-mg group was higher owing to potential hemoglobin increases, as determined by pharmacokinetic modeling. On the basis of these assumptions, we estimated a sample size of approximately 100 patients to be randomly assigned in the ratio of 3:3:4 across the three groups.</div><div role="paragraph">All the efficacy and safety analyses were performed in the intention-to-treat population, which included all the patients who underwent randomization. The primary end point was analyzed with the use of an analysis of covariance (ANCOVA) model, with the randomization factor and baseline value as covariates. The analysis was performed with a closed testing procedure for correction of multiplicity and a hierarchical testing procedure. First, the sotatercept 0.7-mg group was compared with the placebo group, followed by a comparison of the sotatercept 0.3-mg group with the placebo group. Multiple imputation was used to handle missing data for all the primary and secondary efficacy end points that were assessed as continuous variables. Other end points were summarized with the use of descriptive statistics and analyzed with an ANCOVA model, as appropriate. Conventional two-sided P values are presented for the primary end point; no P values are presented for secondary and other end points. Sensitivity analyses of the primary and key secondary end points were performed; in one analysis, only the patients who were receiving double or triple therapy for pulmonary arterial hypertension at baseline were included, and in an additional analysis, missing data were imputed with the use of the last-observation-carried-forward method. The underlying normality assumption for ANCOVA was tested with the use of the Shapiro–Wilk test. If the assumption of normality was rejected, the Hodges–Lehmann analysis was used to present the location shift value. Results are reported as point estimates and 95% confidence intervals. The widths of the confidence intervals have not been adjusted for multiple comparisons, so the intervals should not be used to infer definitive treatment effects for the secondary outcomes or subgroup analyses.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Baseline Characteristics and Follow-up</h3><div role="paragraph">From June 2018 through July 2019, a total of 163 patients were screened, of whom 106 underwent randomization at 43 centers in eight countries. Patients were randomly assigned to receive placebo (32 patients), sotatercept at a dose of 0.3 mg per kilogram (32 patients), or sotatercept at a dose of 0.7 mg per kilogram (42 patients), in addition to stable background therapy for pulmonary arterial hypertension (Fig. S1). The reasons for screening failure for the 57 patients who were excluded are provided in Table S3. Demographic and baseline clinical characteristics were similar among the groups, showing a relatively young patient population (mean [±SD] age, 48.3±14.3 years) with moderate-to-severe pulmonary arterial hypertension. In total, 59 of the 106 patients (56%) were receiving triple therapy and 39 (37%) were receiving prostacyclin infusion therapy (<a href="#t1">Table 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t1.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/9e6e790a-4e53-4ecf-b050-334fb73c44df/assets/images/large/nejmoa2024277_t1.jpg" height="2684" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.7 mg/kg<br>(N=42)</th><th class="txxx-borders">Both Sotatercept<br>Dose Groups<br>(N=74)</th><th class="txxr-borders">Total<br>(N=106)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">26 (81)</td><td class="xxxx-borders shading">29 (91)</td><td class="xxxx-borders shading">37 (88)</td><td class="xxxx-borders shading">66 (89)</td><td class="xxxr-borders shading">92 (87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age — yr</td><td class="xxxx-borders">45.6±13.4</td><td class="xxxx-borders">49.1±14.3</td><td class="xxxx-borders">49.8±15.1</td><td class="xxxx-borders">49.5±14.7</td><td class="xxxr-borders">48.3±14.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">30 (94)</td><td class="xxxx-borders">31 (97)</td><td class="xxxx-borders">37 (88)</td><td class="xxxx-borders">68 (92)</td><td class="xxxr-borders">98 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">4 (5)</td><td class="xxxr-borders shading">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (3)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">27.3±5.9</td><td class="xxxx-borders shading">26.1±4.9</td><td class="xxxx-borders shading">27.7±6.6</td><td class="xxxx-borders shading">27.0±5.9</td><td class="xxxr-borders shading">27.1±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Time since diagnosis of pulmonary arterial hypertension — yr<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7.7±5.5</td><td class="xxxx-borders">7.8±6.0</td><td class="xxxx-borders">7.7±5.6</td><td class="xxxx-borders">7.7±5.7</td><td class="xxxr-borders">7.7±5.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Classification of pulmonary arterial hypertension — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Idiopathic</td><td class="xxxx-borders">19 (59)</td><td class="xxxx-borders">13 (41)</td><td class="xxxx-borders">29 (69)</td><td class="xxxx-borders">42 (57)</td><td class="xxxr-borders">61 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Heritable</td><td class="xxxx-borders shading">7 (22)</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxr-borders shading">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Associated with connective-tissue disease</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">9 (28)</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">15 (20)</td><td class="xxxr-borders">18 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Drug-induced or toxin-induced</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">7 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Associated with corrected congenital shunts</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO functional class — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">II</td><td class="xxxx-borders">17 (53)</td><td class="xxxx-borders">15 (47)</td><td class="xxxx-borders">24 (57)</td><td class="xxxx-borders">39 (53)</td><td class="xxxr-borders">56 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">III</td><td class="xxxx-borders shading">15 (47)</td><td class="xxxx-borders shading">17 (53)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxx-borders shading">35 (47)</td><td class="xxxr-borders shading">50 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Standard therapy for pulmonary arterial hypertension — no. (%)<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Prostacyclin infusion therapy</td><td class="xxxx-borders shading">10 (31)</td><td class="xxxx-borders shading">11 (34)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxx-borders shading">29 (39)</td><td class="xxxr-borders shading">39 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Monotherapy</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">7 (9)</td><td class="xxxr-borders">10 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Double therapy</td><td class="xxxx-borders shading">12 (38)</td><td class="xxxx-borders shading">11 (34)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">25 (34)</td><td class="xxxr-borders shading">37 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Triple therapy</td><td class="xxxx-borders">17 (53)</td><td class="xxxx-borders">18 (56)</td><td class="xxxx-borders">24 (57)</td><td class="xxxx-borders">42 (57)</td><td class="xxxr-borders">59 (56)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders shading">13.7±1.8</td><td class="xxxx-borders shading">12.9±1.5</td><td class="xxxx-borders shading">13.5±1.6</td><td class="xxxx-borders shading">13.3±1.6</td><td class="xxxr-borders shading">13.4±1.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Platelet count — ×10<sup>−9</sup> per liter</td><td class="xxxx-borders">202.1±81.7</td><td class="xxxx-borders">204.4±60.8</td><td class="xxxx-borders">206.7±65.3</td><td class="xxxx-borders">205.7±63.0</td><td class="xxxr-borders">204.6±68.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">6-Minute walk distance — m</td><td class="xxxx-borders shading">409.1±63.9</td><td class="xxxx-borders shading">385.9±88.7</td><td class="xxxx-borders shading">397.6±91.6</td><td class="xxxx-borders shading">392.5±89.9</td><td class="xxxr-borders shading">397.5±83.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">NT-proBNP — pg/ml</td><td class="xxxx-borders">870.2±1213.3</td><td class="xxxx-borders">998.5±1267.1</td><td class="xxxx-borders">870.5±1608.7</td><td class="xxxx-borders">924.9±1465.2</td><td class="xxxr-borders">908.2±1387.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Systolic excursion from the tricuspid annular plane — cm</td><td class="xxxx-borders shading">1.8±0.37</td><td class="xxxx-borders shading">1.8±0.24</td><td class="xxxx-borders shading">1.8±0.37</td><td class="xxxx-borders shading">1.8±0.32</td><td class="xxxr-borders shading">1.8±0.34</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pulmonary vascular resistance — dyn·sec·cm<sup>−5</sup></td><td class="xxxx-borders">797.4±322.6</td><td class="xxxx-borders">789.4±287.2</td><td class="xxxx-borders">755.9±411.3</td><td class="xxxx-borders">770.4±361.0</td><td class="xxxr-borders">778.6±348.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Cardiac index — liters/min/m<sup>2</sup></td><td class="xxxx-borders shading">2.5±0.54</td><td class="xxxx-borders shading">2.7±0.69</td><td class="xxxx-borders shading">2.5±0.47</td><td class="xxxx-borders shading">2.6±0.58</td><td class="xxxr-borders shading">2.6±0.56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cardiac output — liters/min</td><td class="xxxx-borders">4.6±0.83</td><td class="xxxx-borders">4.6±1.1</td><td class="xxxx-borders">4.6±1.0</td><td class="xxxx-borders">4.6±1.1</td><td class="xxxr-borders">4.6±0.98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Pulmonary artery pressure — mm Hg</td><td class="xxxx-borders shading">54.1±13.4</td><td class="xxxx-borders shading">53.6±12.2</td><td class="xxxx-borders shading">50.1±12.6</td><td class="xxxx-borders shading">51.6±12.5</td><td class="xxxr-borders shading">52.4±12.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pulmonary artery wedge pressure — mm Hg</td><td class="xxxx-borders">10.4±3.0</td><td class="xxxx-borders">10.7±3.1</td><td class="xxxx-borders">10.0±3.1</td><td class="xxxx-borders">10.3±3.1</td><td class="xxxr-borders">10.3±3.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Right atrial pressure — mm Hg</td><td class="xbxx-borders shading">9.4±5.6</td><td class="xbxx-borders shading">7.9±3.3</td><td class="xbxx-borders shading">7.1±3.8</td><td class="xbxx-borders shading">7.5±3.6</td><td class="xbxr-borders shading">8.1±4.3</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Baseline Clinical Characteristics.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. There were no between-group differences at baseline. Percentages may not total 100 because of rounding. NT-proBNP denotes N-terminal pro–B-type natriuretic peptide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The length of time since the diagnosis of pulmonary arterial hypertension was calculated by adding the number of days from the date of diagnosis to the date of informed consent (enrollment) plus 1 day, then dividing by 365.25.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">World Health Organization (WHO) functional classes range from I to IV, with higher numbers indicating greater functional limitations.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">The standard therapy was not prespecified in the protocol; rather, patients were treated according to their respective physicians and countries. The treatment included monotherapy, double therapy, or triple therapy with endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, or prostacyclin-receptor agonists. Patients who were receiving prostacyclin infusion therapy were also included in one of the other categories of therapy.</div></div></div></figcaption></figure></div><div role="paragraph">The last patient completed the 24-week placebo-controlled treatment period on December 17, 2019, and data were unblinded for analysis on January 8, 2020. Data on cumulative drug exposure during the placebo-controlled treatment period are provided in Table S4.</div></section><section id="sec-2-2"><h3>Primary End Point</h3><div role="paragraph">In the intention-to-treat population at week 24, the least-squares mean change from baseline in pulmonary vascular resistance was a decrease of 162.2 dyn·sec·cm<sup>−5</sup> in the sotatercept 0.3-mg group and a decrease of 255.9 dyn·sec·cm<sup>−5</sup> in the sotatercept 0.7-mg group, as compared with a decrease of 16.4 dyn·sec·cm<sup>−5</sup> in the placebo group. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group at week 24 was −145.8 dyn·sec·cm<sup>−5</sup> (95% confidence interval [CI], −241.0 to −50.6; P=0.003), and the least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −239.5 dyn·sec·cm<sup>−5</sup> (95% CI, −329.3 to −149.7; P&lt;0.001) (<a href="#f2">Figure 2</a> and <a href="#t2">Table 2</a>). Sensitivity analyses showed similar results (Table S5). This treatment effect was consistent across a range of prespecified subgroups, including those that were defined according to background therapy (monotherapy or double therapy vs. triple therapy) and according to prostacyclin infusion therapy (yes vs. no) (Fig. S2). The reduction in pulmonary vascular resistance in the sotatercept groups was driven by a decreased mean pulmonary artery pressure (least-squares mean difference of −8.3 mm Hg [95% CI, −12.7 to −4.0] between the sotatercept 0.3-mg group and the placebo group and of −13.4 mm Hg [95% CI, −17.5 to −9.3] between the sotatercept 0.7-mg group and the placebo group) (Table S6). In contrast, pulmonary artery wedge pressure and cardiac output showed minimal changes across the three groups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f2.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/a5128d13-56ed-4685-bc51-1a283f02fdf2/assets/images/large/nejmoa2024277_f2.jpg" height="3318" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Change in Pulmonary Vascular Resistance from Baseline to Week 24 in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows the least-squares mean change from baseline to week 24 in pulmonary vascular resistance in each group. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group was −145.8 dyn·sec·cm<sup>−5</sup> (95% CI, −241.0 to −50.6). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −239.5 dyn·sec·cm<sup>−5</sup> (95% CI, −329.3 to −149.7); the 0.7-mg group had a 34% reduction from baseline. 𝙸 bars indicate standard errors. Panel B shows pulmonary vascular resistance at baseline and at the end of the placebo-controlled treatment period (week 24) in the three groups. The horizontal line in the boxes represents the median, and the bottom and top of the boxes represent the first and third quartiles, respectively. 𝙸 bars indicate the minimum and maximum range, excluding outliers. Outliers are represented by single point markers (o and x).</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/b304199c-ae8f-4a79-bc6c-84a592d38be9/assets/images/large/nejmoa2024277_t2.jpg" height="1594" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg <br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.7 mg/kg <br>(N=42)</th><th class="txxr-borders">Both Sotatercept<br>Dose Groups<br>(N=74)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Primary End Point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pulmonary vascular resistance — dyn·sec·cm<sup>−5</sup></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">−16.4±35.3</td><td class="xxxx-borders shading">−162.2±33.3</td><td class="xxxx-borders shading">−255.9±29.6</td><td class="xxxr-borders shading">−215.2±22.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−145.8 (−241.0 to −50.6)</td><td class="xxxx-borders">−239.5 (−329.3 to −149.7)</td><td class="xxxr-borders">−198.9 (−281.5 to −116.3)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>Secondary End Points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">6-Minute walk distance — m</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">28.7±9.3</td><td class="xxxx-borders shading">58.1±9.2</td><td class="xxxx-borders shading">50.1±8.2</td><td class="xxxr-borders shading">53.5±6.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">29.4 (3.8 to 55.0)</td><td class="xxxx-borders">21.4 (−2.8 to 45.7)</td><td class="xxxr-borders">24.9 (3.1 to 46.6)</td></tr><tr data-type="row"><td class="xxlx-borders shading">NT-proBNP — pg/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders">310.4±151.3</td><td class="xxxx-borders">−621.1±150.6</td><td class="xxxx-borders">−340.6±139.4</td><td class="xxxr-borders">−462.4±101.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−931.5 (−1353.2 to −509.7)</td><td class="xxxx-borders shading">−651.0 (−1043.3 to −258.7)</td><td class="xxxr-borders shading">−772.1 (−1125.2 to −419.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Systolic excursion from the tricuspid annular plane — cm</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">0.0±0.05</td><td class="xxxx-borders shading">−0.0±0.05</td><td class="xxxx-borders shading">−0.1±0.05</td><td class="xxxr-borders shading">−0.0±0.04</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.0 (−0.15 to 0.15)</td><td class="xxxx-borders">−0.1 (−0.2 to 0.08)</td><td class="xxxr-borders">−0.0 (−0.16 to 0.09)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO functional class</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients with improvement of at least once class — no. (%)</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">10 (31)</td><td class="xxxx-borders">7 (17)</td><td class="xxxr-borders">17 (23)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Clinical worsening</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Patients with a clinical worsening event — no. (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">2 (6)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (2)</td><td class="xbxr-borders">1 (1)</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary Efficacy End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">All the analyses were performed in the intention-to-treat population with standard multiple imputation for handling missing data. The widths of the confidence intervals have not been adjusted for multiple comparisons, so the intervals should not be used to infer definitive treatment effects for the secondary end points.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The definition of a clinical worsening event is provided in the <a href="#ap2">Supplementary Appendix</a>.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Secondary Efficacy End Points</h3><div role="paragraph">In the intention-to-treat population, the least-squares mean change from baseline in 6-minute walk distance at week 24 was an increase of 58.1 m in the sotatercept 0.3-mg group and an increase of 50.1 m in the sotatercept 0.7-mg group, as compared with an increase of 28.7 m in the placebo group (Figs. S3 and S4 and <a href="#t2">Table 2</a>). The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group at week 24 was 29.4 m (95% CI, 3.8 to 55.0), and the least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was 21.4 m (95% CI, −2.8 to 45.7). Sensitivity analyses showed similar results (Table S5).</div><div role="paragraph">At week 24, the least-squares mean change from baseline in the level of NT-proBNP was a decrease of 621.1±150.6 pg per milliliter in the sotatercept 0.3-mg group and a decrease of 340.6±139.4 pg per milliliter in the sotatercept 0.7-mg group, as compared with an increase of 310.4±151.3 pg per milliliter in the placebo group. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group was −931.5 pg per milliliter (95% CI, −1353.2 to −509.7), and the least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −651.0 pg per milliliter (95% CI, −1043.3 to −258.7) (Figs. S5 and S6 and <a href="#t2">Table 2</a>).</div><div role="paragraph">The mean change in systolic excursion of the tricuspid annular plane did not differ significantly between the sotatercept groups and the placebo group. The WHO functional class improved from baseline by at least one class in 4 patients (12%) in the placebo group, in 10 patients (31%) in the sotatercept 0.3-mg group, and in 7 patients (17%) in the sotatercept 0.7-mg group. Clinical worsening events occurred in 2 patients (6%) in the placebo group, in no patients in the sotatercept 0.3-mg group, and in 1 patient (2%) in the sotatercept 0.7-mg group (<a href="#t2">Table 2</a>). On the basis of the scores on the quality-of-life, activity limitation, and symptom scales of the Cambridge Pulmonary Hypertension Outcome Review and the mental and physical component scores on the SF-36, quality of life remained stable for patients in all three groups during the 24-week placebo-controlled treatment period (Table S7).</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">The most commonly reported adverse events throughout the trial are listed in <a href="#t3">Table 3</a>; serious adverse events are detailed in Table S8. Adverse events of CTCAE grade 3 or higher were reported in 3 patients (9%) in the sotatercept 0.3-mg group, in 11 patients (26%) in the sotatercept 0.7-mg group, and in 5 patients (16%) in the placebo group (Table S9).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t3.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/ae30f7b2-eb4f-4b64-ac47-bdefc0bd4137/assets/images/large/nejmoa2024277_t3.jpg" height="1975" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg<br>(N=32)</th><th class="txxr-borders">Sotatercept<br>0.7 mg/kg<br>(N=42)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event — no. (%)</td><td class="xxxx-borders shading">28 (88)</td><td class="xxxx-borders shading">29 (91)</td><td class="xxxr-borders shading">34 (81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse event occurring in ≥10% of patients in any group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">8 (25)</td><td class="xxxr-borders shading">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">7 (22)</td><td class="xxxr-borders">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dizziness</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">5 (16)</td><td class="xxxr-borders">4 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">6 (19)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">4 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">3 (9)</td><td class="xxxr-borders">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event of special interest — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (9)</td><td class="xxxr-borders">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Leukopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">10 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of sotatercept or placebo — no. (%)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">3 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to withdrawal from the trial — no. (%)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">3 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to death — no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (2)<a href="#t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hemoglobin increase reported as an adverse event — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">7 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Change in hematologic variables from baseline to week 24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">30</td><td class="xxxx-borders">31</td><td class="xxxr-borders">36</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders shading">0.0±1.1</td><td class="xxxx-borders shading">1.2±1.2</td><td class="xxxr-borders shading">1.5±1.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Platelet count — ×10<sup>9</sup> per liter</td><td class="xbxx-borders">−6.3±29.1<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders">12.1±47.7</td><td class="xbxr-borders">−12.1±49.8</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events and Hematologic Variables through the End of the Placebo-Controlled Treatment Period.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Plus–minus values are means ±SD.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">This patient died from cardiac arrest. Preexisting risk factors included hypertension, type 2 diabetes, chronic obstructive pulmonary disease, hyperlipidemia, atrial fibrillation, congestive heart disease, and ischemic heart disease. Concomitant medications included furosemide, spironolactone, ambrisentan, tadalafil, apixaban, bisoprolol, digoxin, gliclazide, linagliptin, pravastatin, and tiotropium.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">A total of 29 patients in the placebo group were included in the analysis of platelet count.</div></div></div></figcaption></figure></div><div role="paragraph">Thrombocytopenia was the most common adverse event of special interest, occurring in 2 patients (6%) in the sotatercept 0.3-mg group and in 5 patients (12%) in the sotatercept 0.7-mg group but in no patients in the placebo group. No events of thrombocytopenia-related bleeding were reported during the trial, and no patient received a platelet transfusion. Hemoglobin increase was reported as an adverse event in 1 patient (3%) in the sotatercept 0.3-mg group and in 7 patients (17%) in the sotatercept 0.7-mg group but in no patients in the placebo group. Details of the adverse events of thrombocytopenia and hemoglobin increase are provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">In accordance with protocol-specified criteria, 3 patients (1 in the sotatercept 0.3-mg group and 2 in the sotatercept 0.7-mg group) were withdrawn from the trial because their hemoglobin levels had risen above 18 g per deciliter and because they had undergone protocol-mandated phlebotomy. The occurrence of thrombocytopenia resulted in the discontinuation of sotatercept in 1 patient and the withdrawal of consent in another patient; both were in the sotatercept 0.7-mg group. One patient in the sotatercept 0.7-mg group died from cardiac arrest during the trial.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the PULSAR trial, 24 weeks of treatment with sotatercept resulted in a reduction in pulmonary vascular resistance that was significantly greater than the reduction seen with placebo in patients with pulmonary arterial hypertension. Improvements from baseline in exercise capacity (as assessed by 6-minute walk distance) and NT-proBNP levels were also noted with sotatercept. All the patients had been receiving background therapy with approved agents for pulmonary arterial hypertension before enrollment in the trial and continued the treatment during the trial. The greater degree of reduction in pulmonary vascular resistance as compared with placebo was seen at both dose levels of sotatercept, with the higher dose resulting in a 34% reduction from baseline. Thrombocytopenia and an increased hemoglobin level were the most common hematologic adverse events. One patient in the higher-dose sotatercept group died from cardiac arrest.</div><div role="paragraph">Sotatercept was shown to reduce pulmonary vascular resistance in patients receiving background monotherapy, double therapy, or triple therapy, including those who were receiving prostacyclin infusion therapy. The decrease in pulmonary vascular resistance in the sotatercept groups was achieved by reducing the mean pulmonary artery pressure, without causing a substantial change in cardiac output or pulmonary artery wedge pressure. Preclinical evidence suggests that sotatercept has a direct effect on pulmonary vascular remodeling, which may explain its clinical effect on pulmonary artery pressure.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup></div><div role="paragraph">Thrombocytopenia was the most common adverse event of special interest but was not associated with bleeding events in this trial; all the events were reversible after delay, reduction, or discontinuation of sotatercept or placebo. The observed increases in hemoglobin levels are consistent with the erythropoietic effects of sotatercept seen in previous clinical trials.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19 r20 r21 r22 r23 r24" id="body-ref-r24-2" href-manipulated="true">18-24</a></sup> Mean hemoglobin levels remained elevated throughout the treatment period in both sotatercept groups, and 3 patients discontinued sotatercept or placebo in accordance with the protocol owing to hemoglobin levels that exceeded the prespecified safety margin of 18 g per deciliter.</div><div role="paragraph">This trial has some limitations. First, as with other phase 2 trials, the sample size was relatively small; however, allowances made for expected dropout rates in each treatment group were sufficient to show improvements with respect to the primary and secondary end points. Second, the duration of the trial was brief at 24 weeks, and the longer-term effects of sotatercept in this clinical context have not been established. Third, the trial was not designed to study the effects of sotatercept on clinical outcomes, including mortality, and this would be important to address in future trials.</div><div role="paragraph">Sotatercept is a first-in-class therapeutic fusion protein that targets an imbalance in activin–growth differentiation factor and BMP pathway signaling. In this trial, treatment with sotatercept reduced pulmonary vascular resistance among patients with pulmonary arterial hypertension who were receiving stable background therapy, including prostacyclin infusion therapy. Concordant improvements from baseline in 6-minute walk distance and NT-proBNP levels were also observed. Additional trials, including a phase 3 trial, are ongoing or planned.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Acceleron Pharma.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and families who participated in the PULSAR trial; the investigators and their research teams who collaborated on the trial; current and former personnel at Acceleron Pharma, including Patrick Andre, Carolyn J. Barron, Erica Davis, Shuree Harrison, Ravindra Kumar, Musa Mutyaba, John Oram, John Quisel, Joseph G. Reynolds, and Carlos Sanmarco; and Zoe Noakes and Sophie Briggs of InterComm International, for medical writing assistance (funded by Acceleron Pharma).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2024277_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024277/suppl_file/nejmoa2024277_protocol.pdf" download="nejmoa2024277_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024277_protocol.pdf" data-doi="10.1056/NEJMoa2024277">Download</a></li><li>6.38 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2024277_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024277/suppl_file/nejmoa2024277_appendix.pdf" download="nejmoa2024277_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024277_appendix.pdf" data-doi="10.1056/NEJMoa2024277">Download</a></li><li>1.04 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2024277_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024277/suppl_file/nejmoa2024277_disclosures.pdf" download="nejmoa2024277_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024277_disclosures.pdf" data-doi="10.1056/NEJMoa2024277">Download</a></li><li>448.76 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2024277_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024277/suppl_file/nejmoa2024277_data-sharing.pdf" download="nejmoa2024277_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024277_data-sharing.pdf" data-doi="10.1056/NEJMoa2024277">Download</a></li><li>67.30 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <em>Eur Respir J</em> 2019;53(1):1801887-1801887.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01887-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545970/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pathology+and+pathobiology+of+pulmonary+hypertension%3A+state+of+the+art+and+research+perspectives.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801887-1801887&amp;doi=10.1183%2F13993003.01887-2018&amp;pmid=30545970" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progressive right ventricular dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] pulmonary vascular remodeling pathways. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <em>Eur Heart J</em> 2016;37:67-119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehv317" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26320113/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380177200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension.&amp;publication_year=2016&amp;journal=Eur+Heart+J&amp;pages=67-119&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;pmid=26320113" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progressive right ventricular dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and human immunodeficiency virus infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <em>Circulation</em> 2014;130:2189-2208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.114.006974" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25602947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346141900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Advances+in+therapeutic+interventions+for+patients+with+pulmonary+arterial+hypertension.&amp;publication_year=2014&amp;journal=Circulation&amp;pages=2189-2208&amp;doi=10.1161%2FCIRCULATIONAHA.114.006974&amp;pmid=25602947" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. <em>Eur Respir J</em> 2019;53(1):1801908-1801908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01908-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545975/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+trial+design+and+new+therapies+for+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801908-1801908&amp;doi=10.1183%2F13993003.01908-2018&amp;pmid=30545975" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. <em>Chest</em> 2015;148:1043-1054.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.15-0300" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26066077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363956300045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Five-year+outcomes+of+patients+enrolled+in+the+REVEAL+Registry.&amp;publication_year=2015&amp;journal=Chest&amp;pages=1043-1054&amp;doi=10.1378%2Fchest.15-0300&amp;pmid=26066077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. <em>Eur Heart J</em> 2018;39:4175-4181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehx257" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28575277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000456854500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+comprehensive+risk+stratification+at+early+follow-up+determines+prognosis+in+pulmonary+arterial+hypertension.&amp;publication_year=2018&amp;journal=Eur+Heart+J&amp;pages=4175-4181&amp;doi=10.1093%2Feurheartj%2Fehx257&amp;pmid=28575277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Olsson KM, Richter MJ, Kamp JC, et al. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <em>J Heart Lung Transplant</em> 2019;38:748-756.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.healun.2019.05.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31128966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473321800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+treprostinil+as+an+add-on+therapy+in+patients+with+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=J+Heart+Lung+Transplant&amp;pages=748-756&amp;doi=10.1016%2Fj.healun.2019.05.002&amp;pmid=31128966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. <em>Am J Hum Genet</em> 2000;67:737-744.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/303059" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10903931/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089002300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+primary+pulmonary+hypertension+%28gene+PPH1%29+is+caused+by+mutations+in+the+bone+morphogenetic+protein+receptor-II+gene.&amp;publication_year=2000&amp;journal=Am+J+Hum+Genet&amp;pages=737-744&amp;doi=10.1086%2F303059&amp;pmid=10903931" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. <em>Circulation</em> 2002;105:1672-1678.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/01.CIR.0000012754.72951.3D" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11940546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000174987300193" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Primary+pulmonary+hypertension+is+associated+with+reduced+pulmonary+vascular+expression+of+type+II+bone+morphogenetic+protein+receptor.&amp;publication_year=2002&amp;journal=Circulation&amp;pages=1672-1678&amp;doi=10.1161%2F01.CIR.0000012754.72951.3D&amp;pmid=11940546" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients without heritable disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and pulmonary vascular remodeling. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. <em>Circulation</em> 2001;104:790-795.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/hc3201.094152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11502704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170505800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Altered+growth+responses+of+pulmonary+artery+smooth+muscle+cells+from+patients+with+primary+pulmonary+hypertension+to+transforming+growth+factor-beta%281%29+and+bone+morphogenetic+proteins.&amp;publication_year=2001&amp;journal=Circulation&amp;pages=790-795&amp;doi=10.1161%2Fhc3201.094152&amp;pmid=11502704" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients without heritable disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and pulmonary vascular remodeling. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Guignabert C, Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. <em>Eur Respir J</em> 2021;57(2):2002341-2002341.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.02341-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32817256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000619682500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+transforming+growth+factor-%CE%B2+receptors+in+pulmonary+hypertension.&amp;publication_year=2021&amp;journal=Eur+Respir+J&amp;pages=2002341-2002341&amp;doi=10.1183%2F13993003.02341-2020&amp;pmid=32817256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. <em>Circ Res</em> 2005;96:1053-1063.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/01.RES.0000166926.54293.68" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15845886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229396500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dysfunctional+Smad+signaling+contributes+to+abnormal+smooth+muscle+cell+proliferation+in+familial+pulmonary+arterial+hypertension.&amp;publication_year=2005&amp;journal=Circ+Res&amp;pages=1053-1063&amp;doi=10.1161%2F01.RES.0000166926.54293.68&amp;pmid=15845886" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Yndestad A, Larsen K-O, Oie E, et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension. <em>J Appl Physiol (1985)</em> 2009;106:1356-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1152/japplphysiol.90719.2008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19196915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264753000042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Elevated+levels+of+activin+A+in+clinical+and+experimental+pulmonary+hypertension.&amp;publication_year=2009&amp;journal=J+Appl+Physiol+%281985%29&amp;pages=1356-1364&amp;doi=10.1152%2Fjapplphysiol.90719.2008&amp;pmid=19196915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. <em>Eur Respir J</em> 2019;53(1):1801899-1801899.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01899-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetics+and+genomics+of+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801899-1801899&amp;doi=10.1183%2F13993003.01899-2018&amp;pmid=30545973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">David L, Mallet C, Mazerbourg S, Feige J-J, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. <em>Blood</em> 2007;109:1953-1961.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-034124" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17068149/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244641100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+BMP9+and+BMP10+as+functional+activators+of+the+orphan+activin+receptor-like+kinase+1+%28ALK1%29+in+endothelial+cells.&amp;publication_year=2007&amp;journal=Blood&amp;pages=1953-1961&amp;doi=10.1182%2Fblood-2006-07-034124&amp;pmid=17068149" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. <em>J Biol Chem</em> 2009;284:15794-15804.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1074/jbc.M109.002881" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19366699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266501000048" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bone+morphogenetic+protein+%28BMP%29+and+activin+type+II+receptors+balance+BMP9+signals+mediated+by+activin+receptor-like+kinase-1+in+human+pulmonary+artery+endothelial+cells.&amp;publication_year=2009&amp;journal=J+Biol+Chem&amp;pages=15794-15804&amp;doi=10.1074%2Fjbc.M109.002881&amp;pmid=19366699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. <em>Sci Transl Med</em> 2020;12(543):eaaz5660-eaaz5660.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aaz5660" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32404506/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533545900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACTRIIA-Fc+rebalances+activin%2FGDF+versus+BMP+signaling+in+pulmonary+hypertension.&amp;publication_year=2020&amp;journal=Sci+Transl+Med&amp;pages=eaaz5660-eaaz5660&amp;doi=10.1126%2Fscitranslmed.aaz5660&amp;pmid=32404506" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Figure 1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] effect on pulmonary artery pressure. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. <em>Support Care Cancer</em> 2016;24:1517-1525.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00520-015-2929-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26370220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373159000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+%28ACE-011%29+for+the+treatment+of+chemotherapy-induced+anemia+in+patients+with+metastatic+breast+cancer+or+advanced+or+metastatic+solid+tumors+treated+with+platinum-based+chemotherapeutic+regimens%3A+results+from+two+phase+2+studies.&amp;publication_year=2016&amp;journal=Support+Care+Cancer&amp;pages=1517-1525&amp;doi=10.1007%2Fs00520-015-2929-9&amp;pmid=26370220" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. <em>Br J Haematol</em> 2014;165:814-823.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24650009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337520600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+in+patients+with+osteolytic+lesions+of+multiple+myeloma.&amp;publication_year=2014&amp;journal=Br+J+Haematol&amp;pages=814-823&amp;doi=10.1111%2Fbjh.12835&amp;pmid=24650009" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. <em>J Bone Miner Res</em> 2009;24:744-752.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1359/jbmr.081208" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19049340/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264724700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single-dose%2C+randomized%2C+double-blind%2C+placebo-controlled+study+of+ACE-011+%28ActRIIA-IgG1%29+in+postmenopausal+women.&amp;publication_year=2009&amp;journal=J+Bone+Miner+Res&amp;pages=744-752&amp;doi=10.1359%2Fjbmr.081208&amp;pmid=19049340" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <em>Lancet Haematol</em> 2018;5(2):e63-e72.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3026(18)30002-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29331635/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423841500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+with+long-term+extension+for+the+treatment+of+anaemia+in+patients+with+lower-risk+myelodysplastic+syndromes%3A+a+phase+2%2C+dose-ranging+trial.&amp;publication_year=2018&amp;journal=Lancet+Haematol&amp;pages=e63-e72&amp;doi=10.1016%2FS2352-3026%2818%2930002-4&amp;pmid=29331635" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. <em>Haematologica</em> 2019;104:477-484.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2018.198887" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30337358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460110400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept%2C+a+novel+transforming+growth+factor+%CE%B2+ligand+trap%2C+improves+anemia+in+%CE%B2-thalassemia%3A+a+phase+II%2C+open-label%2C+dose-finding+study.&amp;publication_year=2019&amp;journal=Haematologica&amp;pages=477-484&amp;doi=10.3324%2Fhaematol.2018.198887&amp;pmid=30337358" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Coyne DW, Singh HN, Smith WT, et al. Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. <em>Kidney Int Rep</em> 2019;4:1585-1597.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ekir.2019.08.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31891000/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000494963400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+safety+and+effects+on+hemoglobin%2C+bone%2C+and+vascular+calcification.&amp;publication_year=2019&amp;journal=Kidney+Int+Rep&amp;pages=1585-1597&amp;doi=10.1016%2Fj.ekir.2019.08.001&amp;pmid=31891000" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Sherman ML, Borgstein NG, Mook L, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. <em>J Clin Pharmacol</em> 2013;53:1121-1130.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.160" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23939631/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325865700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple-dose%2C+safety%2C+pharmacokinetic%2C+and+pharmacodynamic+study+of+sotatercept+%28ActRIIA-IgG1%29%2C+a+novel+erythropoietic+agent%2C+in+healthy+postmenopausal+women.&amp;publication_year=2013&amp;journal=J+Clin+Pharmacol&amp;pages=1121-1130&amp;doi=10.1002%2Fjcph.160&amp;pmid=23939631" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Declaration of Helsinki (1964). <em>BMJ</em> 1996;313:1448-1449.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.313.7070.1448a" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996VX61200033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Declaration+of+Helsinki+%281964%29&amp;publication_year=1996&amp;journal=BMJ&amp;pages=1448-1449&amp;doi=10.1136%2Fbmj.313.7070.1448a" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">van Delden JJ, van der Graaf R. Revised CIOMS international ethical guidelines for health-related research involving humans. <em>JAMA</em> 2017;317:135-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2016.18977" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27923072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391826200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+CIOMS+international+ethical+guidelines+for+health-related+research+involving+humans.&amp;publication_year=2017&amp;journal=JAMA&amp;pages=135-136&amp;doi=10.1001%2Fjama.2016.18977&amp;pmid=27923072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">International Council for Harmonisation. Guidelines for good clinical practice. London: European Medicines Agency, 2002.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=International+Council+for+Harmonisation.+Guidelines+for+good+clinical+practice.+London%3A+European+Medicines+Agency%2C+2002." target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/13"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">13</span></span> • <span property="datePublished">April 1, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1204</span>-<span property="pageEnd">1215</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 31, 2021</div><div><b class="core-label">Published in issue</b>: April 1, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Marc</span> <span property="familyName">Humbert</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vallerie</span> <span property="familyName">McLaughlin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">J. Simon R.</span> <span property="familyName">Gibbs</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mardi</span> <span property="familyName">Gomberg-Maitland</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marius M.</span> <span property="familyName">Hoeper</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ioana R.</span> <span property="familyName">Preston</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1378-7362" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1378-7362</a></span>, <span property="author" typeof="Person"><span property="givenName">Rogerio</span> <span property="familyName">Souza</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2789-9143" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2789-9143</a></span>, <span property="author" typeof="Person"><span property="givenName">Aaron</span> <span property="familyName">Waxman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pilar</span> <span property="familyName">Escribano Subias</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jeremy</span> <span property="familyName">Feldman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gisela</span> <span property="familyName">Meyer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Montani</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Karen M.</span> <span property="familyName">Olsson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Solaiappan</span> <span property="familyName">Manimaran</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jennifer</span> <span property="familyName">Barnes</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter G.</span> <span property="familyName">Linde</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Janethe</span> <span property="familyName">de Oliveira Pena</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">David B.</span> <span property="familyName">Badesch</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the PULSAR Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche 999, Université Paris-Saclay, Le Kremlin-Bicêtre, France (M.H., D.M.); the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor (V.M.); the National Heart and Lung Institute, Imperial College London, and the National Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London (J.S.R.G.); the Department of Medicine, George Washington University, Washington, DC (M.G.-M.); the Department of Respiratory Medicine, Hannover Medical School, and the German Center for Lung Research — both in Hannover, Germany (M.M.H., K.M.O.); the Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center (I.R.P.), and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital (A.W.), Boston, and Acceleron Pharma, Cambridge (S.M., J.B., P.G.L., J.O.P.) — all in Massachusetts; the Pulmonary Division–Heart Institute, University of São Paulo Medical School, São Paulo (R.S.), and Complexo Hospitalar Santa Casa de Porto Alegre, Pulmonary Vascular Research Institute, Porto Alegre (G.M.) — both in Brazil; the Department of Cardiology, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid (P.E.S.); Arizona Pulmonary Specialists, Phoenix (J.F.); and the Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, University of Colorado, Anschutz Medical Campus, Aurora (D.B.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Badesch at Anshutz Medical Campus, University of Colorado, Denver, 12401 E. 17th Ave., Leprino Bldg., Rm. 536, Aurora, CO 80045, or at <a href="mailto:david.badesch@cuanschutz.edu">david.badesch@cuanschutz.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A list of investigators in the PULSAR trial is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Humbert and McLaughlin contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">371</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2024277" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="8dacdc72-d044-2703-eef3-242a65d0eafd"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441" style="display:inline-block;">
                <img alt="Article has an altmetric score of 239" src="https://badges.altmetric.com/?size=320&amp;score=239&amp;types=mabrtwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_8dacdc72-d044-2703-eef3-242a65d0eafd" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=news">
          Picked up by <b>18</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=twitter">
          Posted by <b>137</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=patents">
          Referenced in <b>3</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072441&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>371</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6759910a6f1f3-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2024277"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2024277%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="371" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jyoti Bajpai, </li><li class="list-inline-item cited-by__entry__author">Mehul Saxena, </li><li class="list-inline-item cited-by__entry__author">Akshyaya Pradhan, </li><li class="list-inline-item cited-by__entry__author">Surya Kant, </li></ul><span class="cited-by__entry__title">Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation, </span><span class="cited-by__entry__series-title">World Journal of Methodology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.5662/wjm.v15.i3.102688" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.5662/wjm.v15.i3.102688</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.5662/wjm.v15.i3.102688" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sophia Anastasia Mouratoglou, </li><li class="list-inline-item cited-by__entry__author">Alexandra Arvanitaki, </li><li class="list-inline-item cited-by__entry__author">George Papadopoulos, </li><li class="list-inline-item cited-by__entry__author">Rogerio Souza, </li><li class="list-inline-item cited-by__entry__author">George Giannakoulas, </li></ul><span class="cited-by__entry__title">Pulmonary arterial hypertension treatment. A new era, </span><span class="cited-by__entry__series-title">International Journal of Cardiology Congenital Heart Disease, </span><span class="cited-by__entry__volume"><strong>21</strong>, </span><span class="cited-by__entry__page-range">(100594), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ijcchd.2025.100594" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijcchd.2025.100594</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijcchd.2025.100594" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Aiping Wang, </li><li class="list-inline-item cited-by__entry__author">Qin Pan, </li><li class="list-inline-item cited-by__entry__author">Jing Zhang, </li><li class="list-inline-item cited-by__entry__author">Shaoxin Gong, </li><li class="list-inline-item cited-by__entry__author">Fumei Zhang, </li><li class="list-inline-item cited-by__entry__author">Na Liang, </li><li class="list-inline-item cited-by__entry__author">Yunhua Yang, </li><li class="list-inline-item cited-by__entry__author">Zhisheng Jiang, </li></ul><span class="cited-by__entry__title">Role of inflammation in endothelial responses in Pulmonary Hypertension, </span><span class="cited-by__entry__series-title">Biomedicine &amp; Pharmacotherapy, </span><span class="cited-by__entry__volume"><strong>188</strong>, </span><span class="cited-by__entry__page-range">(118206), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.biopha.2025.118206" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.biopha.2025.118206</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.biopha.2025.118206" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bradley A. Maron, </li></ul><span class="cited-by__entry__title">Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response, </span><span class="cited-by__entry__series-title">American Journal of Respiratory and Critical Care Medicine, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(906-907), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1164/rccm.202503-0539ED" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1164/rccm.202503-0539ED</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1164/rccm.202503-0539ED" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexander M. K. Rothman, </li><li class="list-inline-item cited-by__entry__author">Sofia S. Villar, </li><li class="list-inline-item cited-by__entry__author">Jennifer Middleton, </li><li class="list-inline-item cited-by__entry__author">Andreas A. Roussakis, </li><li class="list-inline-item cited-by__entry__author">Frances Varian, </li><li class="list-inline-item cited-by__entry__author">Hamza Zafar, </li><li class="list-inline-item cited-by__entry__author">Martin Law, </li><li class="list-inline-item cited-by__entry__author">Jane Apperley, </li><li class="list-inline-item cited-by__entry__author">Imke H. Bartelink, </li><li class="list-inline-item cited-by__entry__author">Medhat M. Said, </li><li class="list-inline-item cited-by__entry__author">Juan A. Delgado-SanMartin, </li><li class="list-inline-item cited-by__entry__author">David G. Kiely, </li><li class="list-inline-item cited-by__entry__author">Luke Howard, </li><li class="list-inline-item cited-by__entry__author">Mark Toshner, </li><li class="list-inline-item cited-by__entry__author">S. John Wort, </li><li class="list-inline-item cited-by__entry__author">Martin R. Wilkins, </li></ul><span class="cited-by__entry__title">Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study, </span><span class="cited-by__entry__series-title">American Journal of Respiratory and Critical Care Medicine, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1018-1027), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1164/rccm.202410-1929OC" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1164/rccm.202410-1929OC</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1164/rccm.202410-1929OC" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">David Montani, </li><li class="list-inline-item cited-by__entry__author">Vallerie V. McLaughlin, </li><li class="list-inline-item cited-by__entry__author">J. Simon R. Gibbs, </li><li class="list-inline-item cited-by__entry__author">Mardi Gomberg-Maitland, </li><li class="list-inline-item cited-by__entry__author">Marius M. Hoeper, </li><li class="list-inline-item cited-by__entry__author">Ioana R. Preston, </li><li class="list-inline-item cited-by__entry__author">Rogerio Souza, </li><li class="list-inline-item cited-by__entry__author">Aaron B. Waxman, </li><li class="list-inline-item cited-by__entry__author">Pilar Escribano Subias, </li><li class="list-inline-item cited-by__entry__author">Jeremy Feldman, </li><li class="list-inline-item cited-by__entry__author">Gisela M. Meyer, </li><li class="list-inline-item cited-by__entry__author">Karen M. Olsson, </li><li class="list-inline-item cited-by__entry__author">Florence Coulet, </li><li class="list-inline-item cited-by__entry__author">Solaiappan Manimaran, </li><li class="list-inline-item cited-by__entry__author">Yujie Zhao, </li><li class="list-inline-item cited-by__entry__author">Anna Lau, </li><li class="list-inline-item cited-by__entry__author">Janethe de Oliveira Pena, </li><li class="list-inline-item cited-by__entry__author">David B. Badesch, </li><li class="list-inline-item cited-by__entry__author">Marc Humbert, </li></ul><span class="cited-by__entry__title">
              Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in
              BMPR2
              Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)
            , </span><span class="cited-by__entry__series-title">American Journal of Respiratory and Critical Care Medicine, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1028-1037), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1164/rccm.202409-1698OC" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1164/rccm.202409-1698OC</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1164/rccm.202409-1698OC" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bradley A. Maron, </li></ul><span class="cited-by__entry__title">Sotatercept and the Clinical Transformation of Pulmonary Arterial Hypertension, </span><span class="cited-by__entry__series-title">New England Journal of Medicine, </span><span class="cited-by__entry__volume"><strong>392</strong>, </span><span class="cited-by__entry__issue">20, </span><span class="cited-by__entry__page-range">(2059-2061), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="/doi/full/10.1056/NEJMe2503944" title="Abstract" target="_self" class="cited-by__entry__doi">/doi/full/10.1056/NEJMe2503944</a><div class="cited-by__entry__extra-links"><a href="/doi/full/10.1056/NEJMe2503944" target="_self" class="cited-by__entry__visitable">Abstract</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Suzan Al-Gburi, </li><li class="list-inline-item cited-by__entry__author">Pia Moinzadeh, </li><li class="list-inline-item cited-by__entry__author">Thomas Krieg, </li></ul><span class="cited-by__entry__title">Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives, </span><span class="cited-by__entry__series-title">Sclerosis, </span><span class="cited-by__entry__volume"><strong>3</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(17), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/sclerosis3020017" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/sclerosis3020017</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/sclerosis3020017" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rodolfo A. Estrada, </li><li class="list-inline-item cited-by__entry__author">Sandeep Sahay, </li><li class="list-inline-item cited-by__entry__author">Adriano R. Tonelli, </li></ul><span class="cited-by__entry__title">Treatment of pulmonary hypertension after seven world symposia, </span><span class="cited-by__entry__series-title">Therapeutic Advances in Respiratory Disease, </span><span class="cited-by__entry__volume"><strong>19</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/17534666251342898" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/17534666251342898</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/17534666251342898" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elisabeth Fließer, </li><li class="list-inline-item cited-by__entry__author">Katharina Jandl, </li><li class="list-inline-item cited-by__entry__author">Shiau-Haln Chen, </li><li class="list-inline-item cited-by__entry__author">Mei-Tzu Wang, </li><li class="list-inline-item cited-by__entry__author">Jonas C. Schupp, </li><li class="list-inline-item cited-by__entry__author">Wolfgang M. Kuebler, </li><li class="list-inline-item cited-by__entry__author">Andrew H. Baker, </li><li class="list-inline-item cited-by__entry__author">Grazyna Kwapiszewska, </li></ul><span class="cited-by__entry__title">Transcriptional signatures of endothelial cells shape immune responses in cardiopulmonary health and disease, </span><span class="cited-by__entry__series-title">JCI Insight, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">10, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1172/jci.insight.191059" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1172/jci.insight.191059</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1172/jci.insight.191059" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2024277%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024277" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2024277" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024277.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f1.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/1e670798-fc31-46f9-a5ab-9dce089749e3/assets/images/large/nejmoa2024277_f1.jpg" height="2095" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Proposed Mechanism of Action for Sotatercept in Pulmonary Arterial Hypertension.</div><div class="notes"><div role="doc-footnote">The proposed mechanism of action involves rebalancing growth-promoting and growth-inhibiting signaling. Pulmonary arterial hypertension is associated with dysregulation of the bone morphogenetic protein (BMP) receptor type II (BMPR-II)–Smad1/5/8 pathway in pulmonary vascular smooth muscle and endothelial cells, causing an imbalance between proproliferative and antiproliferative signaling pathways. BMPR-II–Smad1/5/8 pathway down-regulation leads to increased production of activin ligands, such as activin A, growth differentiation factor 8 (GDF8), and GDF11, which contributes to activin receptor type IIA (ActRIIA)–Smad2/3 pathway up-regulation. Increased phosphorylated Smad (pSmad)2/3 activity promotes expression of the endogenous BMP antagonists gremlin-1 and noggin.Gremlin-1 and noggin further reduce BMP–Smad1/5/8 signaling. The overall result is that antiproliferative signaling is reduced, shifting the balance toward proproliferative activin–Smad2/3 signaling, which leads to pulmonary vascular remodeling. Sotatercept acts to sequester excess ActRIIA ligands, thereby reducing ActRIIA–Smad2/3 signaling to rebalance growth-promoting and growth-inhibiting signaling. ALK denotes activin receptor–like kinase.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f2.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/a5128d13-56ed-4685-bc51-1a283f02fdf2/assets/images/large/nejmoa2024277_f2.jpg" height="3318" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Change in Pulmonary Vascular Resistance from Baseline to Week 24 in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows the least-squares mean change from baseline to week 24 in pulmonary vascular resistance in each group. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group was −145.8 dyn·sec·cm<sup>−5</sup> (95% CI, −241.0 to −50.6). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −239.5 dyn·sec·cm<sup>−5</sup> (95% CI, −329.3 to −149.7); the 0.7-mg group had a 34% reduction from baseline. 𝙸 bars indicate standard errors. Panel B shows pulmonary vascular resistance at baseline and at the end of the placebo-controlled treatment period (week 24) in the three groups. The horizontal line in the boxes represents the median, and the bottom and top of the boxes represent the first and third quartiles, respectively. 𝙸 bars indicate the minimum and maximum range, excluding outliers. Outliers are represented by single point markers (o and x).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2024277/asset/9e6e790a-4e53-4ecf-b050-334fb73c44df/assets/images/large/nejmoa2024277_t1.jpg" height="2684" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.7 mg/kg<br>(N=42)</th><th class="txxx-borders">Both Sotatercept<br>Dose Groups<br>(N=74)</th><th class="txxr-borders">Total<br>(N=106)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">26 (81)</td><td class="xxxx-borders shading">29 (91)</td><td class="xxxx-borders shading">37 (88)</td><td class="xxxx-borders shading">66 (89)</td><td class="xxxr-borders shading">92 (87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age — yr</td><td class="xxxx-borders">45.6±13.4</td><td class="xxxx-borders">49.1±14.3</td><td class="xxxx-borders">49.8±15.1</td><td class="xxxx-borders">49.5±14.7</td><td class="xxxr-borders">48.3±14.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">30 (94)</td><td class="xxxx-borders">31 (97)</td><td class="xxxx-borders">37 (88)</td><td class="xxxx-borders">68 (92)</td><td class="xxxr-borders">98 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">4 (5)</td><td class="xxxr-borders shading">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (3)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">27.3±5.9</td><td class="xxxx-borders shading">26.1±4.9</td><td class="xxxx-borders shading">27.7±6.6</td><td class="xxxx-borders shading">27.0±5.9</td><td class="xxxr-borders shading">27.1±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Time since diagnosis of pulmonary arterial hypertension — yr<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7.7±5.5</td><td class="xxxx-borders">7.8±6.0</td><td class="xxxx-borders">7.7±5.6</td><td class="xxxx-borders">7.7±5.7</td><td class="xxxr-borders">7.7±5.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Classification of pulmonary arterial hypertension — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Idiopathic</td><td class="xxxx-borders">19 (59)</td><td class="xxxx-borders">13 (41)</td><td class="xxxx-borders">29 (69)</td><td class="xxxx-borders">42 (57)</td><td class="xxxr-borders">61 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Heritable</td><td class="xxxx-borders shading">7 (22)</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxr-borders shading">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Associated with connective-tissue disease</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">9 (28)</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">15 (20)</td><td class="xxxr-borders">18 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Drug-induced or toxin-induced</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">7 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Associated with corrected congenital shunts</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">3 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO functional class — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">II</td><td class="xxxx-borders">17 (53)</td><td class="xxxx-borders">15 (47)</td><td class="xxxx-borders">24 (57)</td><td class="xxxx-borders">39 (53)</td><td class="xxxr-borders">56 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">III</td><td class="xxxx-borders shading">15 (47)</td><td class="xxxx-borders shading">17 (53)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxx-borders shading">35 (47)</td><td class="xxxr-borders shading">50 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Standard therapy for pulmonary arterial hypertension — no. (%)<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Prostacyclin infusion therapy</td><td class="xxxx-borders shading">10 (31)</td><td class="xxxx-borders shading">11 (34)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxx-borders shading">29 (39)</td><td class="xxxr-borders shading">39 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Monotherapy</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">7 (9)</td><td class="xxxr-borders">10 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Double therapy</td><td class="xxxx-borders shading">12 (38)</td><td class="xxxx-borders shading">11 (34)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">25 (34)</td><td class="xxxr-borders shading">37 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Triple therapy</td><td class="xxxx-borders">17 (53)</td><td class="xxxx-borders">18 (56)</td><td class="xxxx-borders">24 (57)</td><td class="xxxx-borders">42 (57)</td><td class="xxxr-borders">59 (56)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders shading">13.7±1.8</td><td class="xxxx-borders shading">12.9±1.5</td><td class="xxxx-borders shading">13.5±1.6</td><td class="xxxx-borders shading">13.3±1.6</td><td class="xxxr-borders shading">13.4±1.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Platelet count — ×10<sup>−9</sup> per liter</td><td class="xxxx-borders">202.1±81.7</td><td class="xxxx-borders">204.4±60.8</td><td class="xxxx-borders">206.7±65.3</td><td class="xxxx-borders">205.7±63.0</td><td class="xxxr-borders">204.6±68.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">6-Minute walk distance — m</td><td class="xxxx-borders shading">409.1±63.9</td><td class="xxxx-borders shading">385.9±88.7</td><td class="xxxx-borders shading">397.6±91.6</td><td class="xxxx-borders shading">392.5±89.9</td><td class="xxxr-borders shading">397.5±83.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">NT-proBNP — pg/ml</td><td class="xxxx-borders">870.2±1213.3</td><td class="xxxx-borders">998.5±1267.1</td><td class="xxxx-borders">870.5±1608.7</td><td class="xxxx-borders">924.9±1465.2</td><td class="xxxr-borders">908.2±1387.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Systolic excursion from the tricuspid annular plane — cm</td><td class="xxxx-borders shading">1.8±0.37</td><td class="xxxx-borders shading">1.8±0.24</td><td class="xxxx-borders shading">1.8±0.37</td><td class="xxxx-borders shading">1.8±0.32</td><td class="xxxr-borders shading">1.8±0.34</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pulmonary vascular resistance — dyn·sec·cm<sup>−5</sup></td><td class="xxxx-borders">797.4±322.6</td><td class="xxxx-borders">789.4±287.2</td><td class="xxxx-borders">755.9±411.3</td><td class="xxxx-borders">770.4±361.0</td><td class="xxxr-borders">778.6±348.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Cardiac index — liters/min/m<sup>2</sup></td><td class="xxxx-borders shading">2.5±0.54</td><td class="xxxx-borders shading">2.7±0.69</td><td class="xxxx-borders shading">2.5±0.47</td><td class="xxxx-borders shading">2.6±0.58</td><td class="xxxr-borders shading">2.6±0.56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cardiac output — liters/min</td><td class="xxxx-borders">4.6±0.83</td><td class="xxxx-borders">4.6±1.1</td><td class="xxxx-borders">4.6±1.0</td><td class="xxxx-borders">4.6±1.1</td><td class="xxxr-borders">4.6±0.98</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Pulmonary artery pressure — mm Hg</td><td class="xxxx-borders shading">54.1±13.4</td><td class="xxxx-borders shading">53.6±12.2</td><td class="xxxx-borders shading">50.1±12.6</td><td class="xxxx-borders shading">51.6±12.5</td><td class="xxxr-borders shading">52.4±12.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pulmonary artery wedge pressure — mm Hg</td><td class="xxxx-borders">10.4±3.0</td><td class="xxxx-borders">10.7±3.1</td><td class="xxxx-borders">10.0±3.1</td><td class="xxxx-borders">10.3±3.1</td><td class="xxxr-borders">10.3±3.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Right atrial pressure — mm Hg</td><td class="xbxx-borders shading">9.4±5.6</td><td class="xbxx-borders shading">7.9±3.3</td><td class="xbxx-borders shading">7.1±3.8</td><td class="xbxx-borders shading">7.5±3.6</td><td class="xbxr-borders shading">8.1±4.3</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. There were no between-group differences at baseline. Percentages may not total 100 because of rounding. NT-proBNP denotes N-terminal pro–B-type natriuretic peptide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The length of time since the diagnosis of pulmonary arterial hypertension was calculated by adding the number of days from the date of diagnosis to the date of informed consent (enrollment) plus 1 day, then dividing by 365.25.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">World Health Organization (WHO) functional classes range from I to IV, with higher numbers indicating greater functional limitations.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The standard therapy was not prespecified in the protocol; rather, patients were treated according to their respective physicians and countries. The treatment included monotherapy, double therapy, or triple therapy with endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, or prostacyclin-receptor agonists. Patients who were receiving prostacyclin infusion therapy were also included in one of the other categories of therapy.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Baseline Clinical Characteristics.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2024277/asset/b304199c-ae8f-4a79-bc6c-84a592d38be9/assets/images/large/nejmoa2024277_t2.jpg" height="1594" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg <br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.7 mg/kg <br>(N=42)</th><th class="txxr-borders">Both Sotatercept<br>Dose Groups<br>(N=74)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Primary End Point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pulmonary vascular resistance — dyn·sec·cm<sup>−5</sup></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">−16.4±35.3</td><td class="xxxx-borders shading">−162.2±33.3</td><td class="xxxx-borders shading">−255.9±29.6</td><td class="xxxr-borders shading">−215.2±22.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−145.8 (−241.0 to −50.6)</td><td class="xxxx-borders">−239.5 (−329.3 to −149.7)</td><td class="xxxr-borders">−198.9 (−281.5 to −116.3)</td></tr><tr data-type="row"><td class="xxlx-borders shading"><b>Secondary End Points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders">6-Minute walk distance — m</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">28.7±9.3</td><td class="xxxx-borders shading">58.1±9.2</td><td class="xxxx-borders shading">50.1±8.2</td><td class="xxxr-borders shading">53.5±6.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">29.4 (3.8 to 55.0)</td><td class="xxxx-borders">21.4 (−2.8 to 45.7)</td><td class="xxxr-borders">24.9 (3.1 to 46.6)</td></tr><tr data-type="row"><td class="xxlx-borders shading">NT-proBNP — pg/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders">310.4±151.3</td><td class="xxxx-borders">−621.1±150.6</td><td class="xxxx-borders">−340.6±139.4</td><td class="xxxr-borders">−462.4±101.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−931.5 (−1353.2 to −509.7)</td><td class="xxxx-borders shading">−651.0 (−1043.3 to −258.7)</td><td class="xxxr-borders shading">−772.1 (−1125.2 to −419.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Systolic excursion from the tricuspid annular plane — cm</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean change ±SE from baseline at week 24</td><td class="xxxx-borders shading">0.0±0.05</td><td class="xxxx-borders shading">−0.0±0.05</td><td class="xxxx-borders shading">−0.1±0.05</td><td class="xxxr-borders shading">−0.0±0.04</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference as compared with placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.0 (−0.15 to 0.15)</td><td class="xxxx-borders">−0.1 (−0.2 to 0.08)</td><td class="xxxr-borders">−0.0 (−0.16 to 0.09)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">WHO functional class</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients with improvement of at least once class — no. (%)</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">10 (31)</td><td class="xxxx-borders">7 (17)</td><td class="xxxr-borders">17 (23)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Clinical worsening</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Patients with a clinical worsening event — no. (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">2 (6)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (2)</td><td class="xbxr-borders">1 (1)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">All the analyses were performed in the intention-to-treat population with standard multiple imputation for handling missing data. The widths of the confidence intervals have not been adjusted for multiple comparisons, so the intervals should not be used to infer definitive treatment effects for the secondary end points.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><div class="label">†</div></a><div id="core-t2fn2" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg">The definition of a clinical worsening event is provided in the </a><a href="#ap2">Supplementary Appendix</a>.</div></div></div></figcaption><figcaption><div class="caption">Primary and Secondary Efficacy End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2024277/asset/ae30f7b2-eb4f-4b64-ac47-bdefc0bd4137/assets/images/large/nejmoa2024277_t3.jpg" height="1975" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Placebo<br>(N=32)</th><th class="txxx-borders">Sotatercept<br>0.3 mg/kg<br>(N=32)</th><th class="txxr-borders">Sotatercept<br>0.7 mg/kg<br>(N=42)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event — no. (%)</td><td class="xxxx-borders shading">28 (88)</td><td class="xxxx-borders shading">29 (91)</td><td class="xxxr-borders shading">34 (81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse event occurring in ≥10% of patients in any group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">8 (25)</td><td class="xxxr-borders shading">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">7 (22)</td><td class="xxxr-borders">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders shading">5 (16)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dizziness</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">5 (16)</td><td class="xxxr-borders">4 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">6 (19)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">4 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders">4 (12)</td><td class="xxxx-borders">3 (9)</td><td class="xxxr-borders">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event of special interest — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (9)</td><td class="xxxr-borders">6 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Leukopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">5 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">3 (9)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">10 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of sotatercept or placebo — no. (%)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">3 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to withdrawal from the trial — no. (%)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">3 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to death — no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (2)<a href="#core-t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hemoglobin increase reported as an adverse event — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">7 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Change in hematologic variables from baseline to week 24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients</td><td class="xxxx-borders">30</td><td class="xxxx-borders">31</td><td class="xxxr-borders">36</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders shading">0.0±1.1</td><td class="xxxx-borders shading">1.2±1.2</td><td class="xxxr-borders shading">1.5±1.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Platelet count — ×10<sup>9</sup> per liter</td><td class="xbxx-borders">−6.3±29.1<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders">12.1±47.7</td><td class="xbxr-borders">−12.1±49.8</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">This patient died from cardiac arrest. Preexisting risk factors included hypertension, type 2 diabetes, chronic obstructive pulmonary disease, hyperlipidemia, atrial fibrillation, congestive heart disease, and ischemic heart disease. Concomitant medications included furosemide, spironolactone, ambrisentan, tadalafil, apixaban, bisoprolol, digoxin, gliclazide, linagliptin, pravastatin, and tiotropium.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">A total of 29 patients in the placebo group were included in the analysis of platelet count.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events and Hematologic Variables through the End of the Placebo-Controlled Treatment Period.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024277_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2024277</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <em>Eur Respir J</em> 2019;53(1):1801887-1801887.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01887-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545970/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pathology+and+pathobiology+of+pulmonary+hypertension%3A+state+of+the+art+and+research+perspectives.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801887-1801887&amp;doi=10.1183%2F13993003.01887-2018&amp;pmid=30545970" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progressive right ventricular dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] pulmonary vascular remodeling pathways. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <em>Eur Heart J</em> 2016;37:67-119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehv317" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26320113/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380177200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension.&amp;publication_year=2016&amp;journal=Eur+Heart+J&amp;pages=67-119&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;pmid=26320113" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] progressive right ventricular dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and human immunodeficiency virus infection. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <em>Circulation</em> 2014;130:2189-2208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.114.006974" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25602947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346141900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Advances+in+therapeutic+interventions+for+patients+with+pulmonary+arterial+hypertension.&amp;publication_year=2014&amp;journal=Circulation&amp;pages=2189-2208&amp;doi=10.1161%2FCIRCULATIONAHA.114.006974&amp;pmid=25602947" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. <em>Eur Respir J</em> 2019;53(1):1801908-1801908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01908-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545975/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+trial+design+and+new+therapies+for+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801908-1801908&amp;doi=10.1183%2F13993003.01908-2018&amp;pmid=30545975" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. <em>Chest</em> 2015;148:1043-1054.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.15-0300" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26066077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363956300045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Five-year+outcomes+of+patients+enrolled+in+the+REVEAL+Registry.&amp;publication_year=2015&amp;journal=Chest&amp;pages=1043-1054&amp;doi=10.1378%2Fchest.15-0300&amp;pmid=26066077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. <em>Eur Heart J</em> 2018;39:4175-4181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehx257" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28575277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000456854500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+comprehensive+risk+stratification+at+early+follow-up+determines+prognosis+in+pulmonary+arterial+hypertension.&amp;publication_year=2018&amp;journal=Eur+Heart+J&amp;pages=4175-4181&amp;doi=10.1093%2Feurheartj%2Fehx257&amp;pmid=28575277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Olsson KM, Richter MJ, Kamp JC, et al. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <em>J Heart Lung Transplant</em> 2019;38:748-756.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.healun.2019.05.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31128966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473321800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+treprostinil+as+an+add-on+therapy+in+patients+with+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=J+Heart+Lung+Transplant&amp;pages=748-756&amp;doi=10.1016%2Fj.healun.2019.05.002&amp;pmid=31128966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. <em>Am J Hum Genet</em> 2000;67:737-744.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/303059" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10903931/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000089002300019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+primary+pulmonary+hypertension+%28gene+PPH1%29+is+caused+by+mutations+in+the+bone+morphogenetic+protein+receptor-II+gene.&amp;publication_year=2000&amp;journal=Am+J+Hum+Genet&amp;pages=737-744&amp;doi=10.1086%2F303059&amp;pmid=10903931" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. <em>Circulation</em> 2002;105:1672-1678.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/01.CIR.0000012754.72951.3D" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11940546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000174987300193" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Primary+pulmonary+hypertension+is+associated+with+reduced+pulmonary+vascular+expression+of+type+II+bone+morphogenetic+protein+receptor.&amp;publication_year=2002&amp;journal=Circulation&amp;pages=1672-1678&amp;doi=10.1161%2F01.CIR.0000012754.72951.3D&amp;pmid=11940546" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients without heritable disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and pulmonary vascular remodeling. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. <em>Circulation</em> 2001;104:790-795.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/hc3201.094152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11502704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000170505800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Altered+growth+responses+of+pulmonary+artery+smooth+muscle+cells+from+patients+with+primary+pulmonary+hypertension+to+transforming+growth+factor-beta%281%29+and+bone+morphogenetic+proteins.&amp;publication_year=2001&amp;journal=Circulation&amp;pages=790-795&amp;doi=10.1161%2Fhc3201.094152&amp;pmid=11502704" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in patients without heritable disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and pulmonary vascular remodeling. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Guignabert C, Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. <em>Eur Respir J</em> 2021;57(2):2002341-2002341.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.02341-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32817256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000619682500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+transforming+growth+factor-%CE%B2+receptors+in+pulmonary+hypertension.&amp;publication_year=2021&amp;journal=Eur+Respir+J&amp;pages=2002341-2002341&amp;doi=10.1183%2F13993003.02341-2020&amp;pmid=32817256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. <em>Circ Res</em> 2005;96:1053-1063.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/01.RES.0000166926.54293.68" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15845886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229396500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dysfunctional+Smad+signaling+contributes+to+abnormal+smooth+muscle+cell+proliferation+in+familial+pulmonary+arterial+hypertension.&amp;publication_year=2005&amp;journal=Circ+Res&amp;pages=1053-1063&amp;doi=10.1161%2F01.RES.0000166926.54293.68&amp;pmid=15845886" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Yndestad A, Larsen K-O, Oie E, et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension. <em>J Appl Physiol (1985)</em> 2009;106:1356-1364.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1152/japplphysiol.90719.2008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19196915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264753000042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Elevated+levels+of+activin+A+in+clinical+and+experimental+pulmonary+hypertension.&amp;publication_year=2009&amp;journal=J+Appl+Physiol+%281985%29&amp;pages=1356-1364&amp;doi=10.1152%2Fjapplphysiol.90719.2008&amp;pmid=19196915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. <em>Eur Respir J</em> 2019;53(1):1801899-1801899.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01899-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000458462600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetics+and+genomics+of+pulmonary+arterial+hypertension.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1801899-1801899&amp;doi=10.1183%2F13993003.01899-2018&amp;pmid=30545973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">David L, Mallet C, Mazerbourg S, Feige J-J, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. <em>Blood</em> 2007;109:1953-1961.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-034124" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17068149/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244641100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identification+of+BMP9+and+BMP10+as+functional+activators+of+the+orphan+activin+receptor-like+kinase+1+%28ALK1%29+in+endothelial+cells.&amp;publication_year=2007&amp;journal=Blood&amp;pages=1953-1961&amp;doi=10.1182%2Fblood-2006-07-034124&amp;pmid=17068149" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. <em>J Biol Chem</em> 2009;284:15794-15804.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1074/jbc.M109.002881" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19366699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266501000048" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bone+morphogenetic+protein+%28BMP%29+and+activin+type+II+receptors+balance+BMP9+signals+mediated+by+activin+receptor-like+kinase-1+in+human+pulmonary+artery+endothelial+cells.&amp;publication_year=2009&amp;journal=J+Biol+Chem&amp;pages=15794-15804&amp;doi=10.1074%2Fjbc.M109.002881&amp;pmid=19366699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. <em>Sci Transl Med</em> 2020;12(543):eaaz5660-eaaz5660.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aaz5660" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32404506/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000533545900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACTRIIA-Fc+rebalances+activin%2FGDF+versus+BMP+signaling+in+pulmonary+hypertension.&amp;publication_year=2020&amp;journal=Sci+Transl+Med&amp;pages=eaaz5660-eaaz5660&amp;doi=10.1126%2Fscitranslmed.aaz5660&amp;pmid=32404506" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Figure 1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] effect on pulmonary artery pressure. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. <em>Support Care Cancer</em> 2016;24:1517-1525.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00520-015-2929-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26370220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373159000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+%28ACE-011%29+for+the+treatment+of+chemotherapy-induced+anemia+in+patients+with+metastatic+breast+cancer+or+advanced+or+metastatic+solid+tumors+treated+with+platinum-based+chemotherapeutic+regimens%3A+results+from+two+phase+2+studies.&amp;publication_year=2016&amp;journal=Support+Care+Cancer&amp;pages=1517-1525&amp;doi=10.1007%2Fs00520-015-2929-9&amp;pmid=26370220" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. <em>Br J Haematol</em> 2014;165:814-823.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24650009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000337520600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+in+patients+with+osteolytic+lesions+of+multiple+myeloma.&amp;publication_year=2014&amp;journal=Br+J+Haematol&amp;pages=814-823&amp;doi=10.1111%2Fbjh.12835&amp;pmid=24650009" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. <em>J Bone Miner Res</em> 2009;24:744-752.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1359/jbmr.081208" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19049340/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264724700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single-dose%2C+randomized%2C+double-blind%2C+placebo-controlled+study+of+ACE-011+%28ActRIIA-IgG1%29+in+postmenopausal+women.&amp;publication_year=2009&amp;journal=J+Bone+Miner+Res&amp;pages=744-752&amp;doi=10.1359%2Fjbmr.081208&amp;pmid=19049340" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. <em>Lancet Haematol</em> 2018;5(2):e63-e72.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3026(18)30002-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29331635/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423841500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+with+long-term+extension+for+the+treatment+of+anaemia+in+patients+with+lower-risk+myelodysplastic+syndromes%3A+a+phase+2%2C+dose-ranging+trial.&amp;publication_year=2018&amp;journal=Lancet+Haematol&amp;pages=e63-e72&amp;doi=10.1016%2FS2352-3026%2818%2930002-4&amp;pmid=29331635" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. <em>Haematologica</em> 2019;104:477-484.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2018.198887" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30337358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460110400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept%2C+a+novel+transforming+growth+factor+%CE%B2+ligand+trap%2C+improves+anemia+in+%CE%B2-thalassemia%3A+a+phase+II%2C+open-label%2C+dose-finding+study.&amp;publication_year=2019&amp;journal=Haematologica&amp;pages=477-484&amp;doi=10.3324%2Fhaematol.2018.198887&amp;pmid=30337358" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Coyne DW, Singh HN, Smith WT, et al. Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. <em>Kidney Int Rep</em> 2019;4:1585-1597.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ekir.2019.08.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31891000/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000494963400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sotatercept+safety+and+effects+on+hemoglobin%2C+bone%2C+and+vascular+calcification.&amp;publication_year=2019&amp;journal=Kidney+Int+Rep&amp;pages=1585-1597&amp;doi=10.1016%2Fj.ekir.2019.08.001&amp;pmid=31891000" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Sherman ML, Borgstein NG, Mook L, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. <em>J Clin Pharmacol</em> 2013;53:1121-1130.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.160" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23939631/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325865700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple-dose%2C+safety%2C+pharmacokinetic%2C+and+pharmacodynamic+study+of+sotatercept+%28ActRIIA-IgG1%29%2C+a+novel+erythropoietic+agent%2C+in+healthy+postmenopausal+women.&amp;publication_year=2013&amp;journal=J+Clin+Pharmacol&amp;pages=1121-1130&amp;doi=10.1002%2Fjcph.160&amp;pmid=23939631" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and end-stage kidney disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] seen in previous clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Declaration of Helsinki (1964). <em>BMJ</em> 1996;313:1448-1449.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.313.7070.1448a" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996VX61200033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Declaration+of+Helsinki+%281964%29&amp;publication_year=1996&amp;journal=BMJ&amp;pages=1448-1449&amp;doi=10.1136%2Fbmj.313.7070.1448a" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">van Delden JJ, van der Graaf R. Revised CIOMS international ethical guidelines for health-related research involving humans. <em>JAMA</em> 2017;317:135-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2016.18977" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27923072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391826200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+CIOMS+international+ethical+guidelines+for+health-related+research+involving+humans.&amp;publication_year=2017&amp;journal=JAMA&amp;pages=135-136&amp;doi=10.1001%2Fjama.2016.18977&amp;pmid=27923072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">International Council for Harmonisation. Guidelines for good clinical practice. London: European Medicines Agency, 2002.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=International+Council+for+Harmonisation.+Guidelines+for+good+clinical+practice.+London%3A+European+Medicines+Agency%2C+2002." target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 30, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2107209" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sotatercept for Pulmonary Arterial Hypertension</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 31, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2036314" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Molecular Rescue in Pulmonary Arterial Hypertension</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.H. Newman</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Presque Isle, Maine</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886432/ob-gyn-physician-full-time-or-part-time-schedule-available-/?query=fjwp&amp;rid=3625">OB/GYN Physician - Full-Time or Part-Time Schedule Available!</a></div></div><div class="nejm-widget_item"><div><span> Tunkhannock, Pennsylvania</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887500/family-medicine-275k-starting-salary-tunkhannock-pa/?query=fjwp&amp;rid=899">Family Medicine - $275K Starting Salary - Tunkhannock, PA</a></div></div><div class="nejm-widget_item"><div><span> Seattle, Washington State</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891270/internal-medicine-physician/?query=fjwf&amp;rid=6691">Internal Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Durham, North Carolina</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886959/general-pediatrics-and-adolescent-health-brier-creek/?query=fjwf&amp;rid=8149">General Pediatrics and Adolescent Health - Brier Creek</a></div></div><div class="nejm-widget_item"><div><span> Los Angeles, California</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883480/hematology-oncology-physicians/?query=fjws&amp;rid=16344">Hematology/Oncology Physicians</a></div></div><div class="nejm-widget_item"><div><span> Connecticut</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890847/orthopedic-total-joint-position-in-southwestern-connecticut-partnership-track/?query=fjwf&amp;rid=5127">Orthopedic Total Joint Position in southwestern Connecticut - Partnership Track</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024277&amp;pubId=41289758&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6759910a6f1f3-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6759910a6f1f3-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6759910a6f1f3-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$261665415$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$261665415$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$261665415$--></div></div><div class="mlt-body"><!--?lit$261665415$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$261665415$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$261665415$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$261665415$-->May 29, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2415160?query=recirc_Semantic" target="_self">Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death</a></div><div class="mlt-article-authors"><!--?lit$261665415$-->M. Humbert and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$261665415$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$261665415$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$261665415$-->Apr 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2213558?query=recirc_Semantic" target="_self">Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension</a></div><div class="mlt-article-authors"><!--?lit$261665415$-->M.M. Hoeper and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$261665415$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$261665415$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$261665415$-->May 29, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2503944?query=recirc_Semantic" target="_self">Sotatercept and the Clinical Transformation of Pulmonary Arterial Hypertension</a></div><div class="mlt-article-authors"><!--?lit$261665415$-->B.A. Maron</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$261665415$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$261665415$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$261665415$-->Apr 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2300324?query=recirc_Semantic" target="_self">Continued Progress in Therapy for Pulmonary Arterial Hypertension</a></div><div class="mlt-article-authors"><!--?lit$261665415$-->D.B. Taichman, J.A. Leopold, and G. Elliott</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$261665415$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$261665415$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$261665415$-->Dec 16, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2000348?query=recirc_Semantic" target="_self">Pulmonary Arterial Hypertension</a></div><div class="mlt-article-authors"><!--?lit$261665415$-->P.M. Hassoun</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2024277?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2024277" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024277.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2024277"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Sotatercept for the Treatment of Pulmonary Arterial Hypertension</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2032125" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2021712" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f1.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/1e670798-fc31-46f9-a5ab-9dce089749e3/assets/images/large/nejmoa2024277_f1.jpg" height="2095" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Proposed Mechanism of Action for Sotatercept in Pulmonary Arterial Hypertension.</div><div class="notes"><div role="doc-footnote">The proposed mechanism of action involves rebalancing growth-promoting and growth-inhibiting signaling. Pulmonary arterial hypertension is associated with dysregulation of the bone morphogenetic protein (BMP) receptor type II (BMPR-II)–Smad1/5/8 pathway in pulmonary vascular smooth muscle and endothelial cells, causing an imbalance between proproliferative and antiproliferative signaling pathways. BMPR-II–Smad1/5/8 pathway down-regulation leads to increased production of activin ligands, such as activin A, growth differentiation factor 8 (GDF8), and GDF11, which contributes to activin receptor type IIA (ActRIIA)–Smad2/3 pathway up-regulation. Increased phosphorylated Smad (pSmad)2/3 activity promotes expression of the endogenous BMP antagonists gremlin-1 and noggin.Gremlin-1 and noggin further reduce BMP–Smad1/5/8 signaling. The overall result is that antiproliferative signaling is reduced, shifting the balance toward proproliferative activin–Smad2/3 signaling, which leads to pulmonary vascular remodeling. Sotatercept acts to sequester excess ActRIIA ligands, thereby reducing ActRIIA–Smad2/3 signaling to rebalance growth-promoting and growth-inhibiting signaling. ALK denotes activin receptor–like kinase.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024277_f2.jpg"><img src="/cms/10.1056/NEJMoa2024277/asset/a5128d13-56ed-4685-bc51-1a283f02fdf2/assets/images/large/nejmoa2024277_f2.jpg" height="3318" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Change in Pulmonary Vascular Resistance from Baseline to Week 24 in the Intention-to-Treat Population.</div><div class="notes"><div role="doc-footnote">Panel A shows the least-squares mean change from baseline to week 24 in pulmonary vascular resistance in each group. The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group was −145.8 dyn·sec·cm<sup>−5</sup> (95% CI, −241.0 to −50.6). The least-squares mean difference between the sotatercept 0.7-mg group and the placebo group was −239.5 dyn·sec·cm<sup>−5</sup> (95% CI, −329.3 to −149.7); the 0.7-mg group had a 34% reduction from baseline. 𝙸 bars indicate standard errors. Panel B shows pulmonary vascular resistance at baseline and at the end of the placebo-controlled treatment period (week 24) in the three groups. The horizontal line in the boxes represents the median, and the bottom and top of the boxes represent the first and third quartiles, respectively. 𝙸 bars indicate the minimum and maximum range, excluding outliers. Outliers are represented by single point markers (o and x).</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Baseline Clinical Characteristics.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Efficacy End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events and Hematologic Variables through the End of the Placebo-Controlled Treatment Period.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/13" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 13</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2032125" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.J. Kelly and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2022516" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">I.B. McInnes and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2024670" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Mbala-Kingebeni and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2024277%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024277&amp;pubId=41289758&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2024277%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024277&amp;pubId=41289758&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05821527815723879" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6759910a6f1f3-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6759910a6f1f3-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6759910a6f1f3-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6759910a6f1f3-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6759910a6f1f3-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6759910a6f1f3-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6759910a6f1f3-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6759910a6f1f3-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6759910a6f1f3-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6759910a6f1f3-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d675990db9f1f3',t:'MTc0OTUzMzI0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d675990db9f1f3&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2024277?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><iframe name="captureIFrame_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-transactionid="822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" id="captureIFrame_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" target="captureIFrame_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="capture_screen"><input id="capture_signIn_js_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="js_version"><input id="capture_signIn_transactionId_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" type="hidden" class="capture_transactionId_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="capture_transactionId"><input id="capture_signIn_form_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="form"><input id="capture_signIn_flow_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="flow"><input id="capture_signIn_client_id_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="client_id"><input id="capture_signIn_redirect_uri_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="redirect_uri"><input id="capture_signIn_response_type_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="response_type"><input id="capture_signIn_flow_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="flow_version"><input id="capture_signIn_settings_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="settings_version"><input id="capture_signIn_locale_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="locale"><input id="capture_signIn_recaptcha_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_822wv040a51g8eahvxbb0zgysiov08dg26iajtnz" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><enk-drpklnohgedo></enk-drpklnohgedo><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>